Anthracycline cardiomyopathy.

Anthracycline cardiomyopathy. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Anthracycline cardiomyopathy. Abstract Text:

N L Kobrinsky,N K Ramsay,W Krivit,

Life-threatening irreversible cardiomyopathy is a major complication of anthracycline therapy, particularly in the pediatric population. The pediatric cardiologist, in concert with the primary oncologist, should therefore play a major role in the care of patients receiving these agents and in clinical trials involving their use. Many risk factors and their relationships to drug pharmacokinetics, mechanisms of action, and toxicity have been identified. These data provide a rational basis for present-day recommendations regarding anthracycline administration and dosage scheduling. They furthermore provide potential avenues for clinical investigation aimed at improving the therapeutic index of these agents: alpha-tocopherol, cytochrome Q10, and other free radical scavengers may decrease the deleterious effects of free radical generation on the myocardium without apparent interference with tumoricidal effect. The cardiac glycosides may decrease cardiac toxicity by specific myocardial exclusion. Anthracycline analogs have been designed to specifically inhibit myocardial binding and/or free radical generation. Clinical trials involving these agents are difficult to interpret because of variability in front end risk factors and dosage schedules in the study population. Furthermore, the relatively low (5 to 10%) incidence of affected patients implies the need for large numbers to demonstrate a statistically significant benefit. Pediatric protocols addressing these issues are urgently needed. Guidelines for present-day management and future studies are outlined.

Anthracycline cardiomyopathy. Publishing Authors By Initials

NL Kobrinsky,NK Ramsay,W Krivit,

For similar organic chemicals: hydrocarbons: hydrocarbons, cyclic: hydrocarbons, aromatic: polycyclic hydrocarbons, aromatic: naphthacenes research abstracts see: organic chemicals: hydrocarbons: hydrocarbons, cyclic: hydrocarbons, aromatic: polycyclic hydrocarbons, aromatic: naphthacenes research

PUBMED ID PMID:

MEDLINE DATE:

Anthracycline cardiomyopathy. Journal Published:

PUBLICATION TYPE: Research Support, U.S. Gov't,

Journal: Pediatric cardiology

VOLUME: 3

Page Numbers: 265-72

Journal Abbreviation: Pediatr Cardiol

ISSN: 0172-0643

DAY: 20

MONTH: 02

YEAR: 1982

Anthracycline cardiomyopathy. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 8003849

Anthracycline cardiomyopathy. Keywords Mesh Terms:

KEYWORDS: Naphthacenes

MESH TERMS: pharmacology

Chemical & Substance for Abstract: Anthracycline cardiomyopathy. Information

Substance Name: Doxorubicin

Registry Number: 23214-92-8

Grant and Affiliation Information for Anthracycline cardiomyopathy.

AFFILIATION:

Country: UNITED STATES

AGENCY: United States NCI

GRANT: CA 07306

ACRONYM: CA

MEDLINETA: Pediatr Cardiol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Anthracycline cardiomyopathy Related Publications

• Adrenoleukodystrophy: a scoring method for brain MR observations.
• Anthracycline cardiomyopathy.
• Changes in platelet microtubules and granules during early clot development.
• Childhood cerebral form of adrenoleukodystrophy: short-term effect of bone marrow transplantation on brain MR observations.
• White matter dysfunction and its neuropsychological correlates: a longitudinal study of a case of metachromatic leukodystrophy treated with bone marrow transplant.